Leuprolide Acetate Market Share, Analysis and Projection, Application, and Region - Global Forecast to 2030
Ngày đăng: 21-09-2023 |
Ngày cập nhật: 21-09-2023
Market Scenario
The leuprolide acetate market size is projected to reach USD 2,400 Million by 2030 at 10.50% CAGR during the forecast period 2022-2030. Leuprolide acetate is a medication used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty . The medication works by decreasing testosterone levels in men and estrogen levels in women . The report states that the increasing prevalence of prostate cancer and endometriosis is expected to drive the growth of the leuprolide acetate market in the projected timeframe .
The report also highlights that side effects such as hot flashes, night sweats, decreased libido, erectile dysfunction, and osteoporosis associated with leuprolide acetate treatment are some factors which will likely act as market restraints for the growth of the leuprolide acetate market in the above mentioned projected timeframe .
Key Players:
GPI Golrang pharmaceutical investment (Russia), Bachem(Switzerland), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.), and others. TOLMAR (Northern Colorado) are some prominent players in the market.
Leuprolide Acetate Market Segmentation
Globally, it has been found that the market is being classified as per the application, mode of administration, and the end-users.
As per the application, the leuprolide acetate industry is being classified into prostate cancer, fibroid of uterine in females, precocious, and many others.
As per the administration, the industry is being divided into intramuscular and subcutaneous. As per the end-user segment, the industry is being classified into hospital units, medicals, clinics, and many more.
Based on end-users the market is being divided into medicals, clinics, research fields, and some academic institutions. As per the geographical analysis, it was found that the market is being classified into some of the European region, the Asian region, North American areas, and some areas of the rest of the world.
Leuprolide Acetate Market-Competitive Landscape
The global Leuprolide Acetate market is characterized by the presence of several well-established and small players, the market appears to be highly competitive and fragmented. Multinational players are increasingly expanding their regional presence in the developing economy, results increase in competition for regional vendors, especially in terms of features such as product differentiation, diverse product portfolios, new trends and quality. The well-established market players are Takeda Pharmaceutical Company Limited, Golrang pharmaceutical investment (GPI), Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited is a pharmaceutical company established in June 1781, headquartered in Japan. Takeda involved in research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It operates in three segments: Prescription Drug, Consumer Healthcare, and Other. Takeda Pharmaceutical is also involved in clinical diagnostics, chemical products, and other businesses. In September 2014, Takeda Pharmaceutical announced that they have submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for Leupin a treatment for prostate cancer and premenopausal breast cancer.
Regional Analysis
Geographically, the global practice analytics market is segmented into the Americas, Europe, Asia-Pacific and Middle East & Africa. North America is anticipated to hold the largest market share during the forecasted period. The major factor influencing the growth of the market include increase in the ageing of population, polycystic ovary syndrome and Alzheimer's disease. Investment in Research and development also drive the demand for leuprolide acetate market in this region. According to Alzheimer organization Alzheimer disease is the 6th largest leading cause of death in United States. It was stated that 5.7 million of Americans population is living with Alzheimer. By, 2050 this number is projected to increase by nearly 14 million. According, to Centers of Disease control and Prevention (CDC) Polycystic Ovary Syndrome (POS) is one of the major causes of female infertility, with 6% to 12% (as many as 5 million) of US women of reproductive age. POS is a insulin resistant in which body make insulin but do not use it completely. As per National institute of health (NIH), in 2015, it was estimated 3,120,176 men living with prostate cancer in the United States. Also, prescribed for the women dealing with endometriosis and Uterine Fibroids, which are one of the most complicated and painful diseases related to female reproductive system. Increase medical professionals has resulted in demand for better standards and quality end products which will further influence the demand in the leuprolide acetate market in the North American region.
Europe is the second largest market followed by Asia-Pacific. The market in this region is expected to witness growth due to rising prevalence of prostate cancer. According to the Cancer Research UK, in 2015, 47151 patients suffered from prostate cancer. Thus driving market growth.
Asia Pacific is estimated to be the fastest growing region and holds the third largest market for leuprolide acetate due to premenstrual syndrome and premenstrual dysphoric (PMS) disorder. Prevalence of PMS among college students is similar to other studies from Asia. According to National Center of Biotechnology Information in India about 27.7% of female population falls in the 15-29 years age-group which is a major driving factor for Leuprolide Acetate Market. The increase in the population of India and China are the major drivers for the market growth.
The Middle East & Africa holds the least market share in leuprolide mark because of poor economy, low government policies, lack of awareness, low per capita income and poor availability of healthcare services.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
